NASDAQ : COYA
Coya Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.98 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 93.36M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 84.68M |
| Enterprise Value | 41.50M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 23.46M |
| Shares Outstanding | 23.46M |
| Shares Change (YoY) | +22.38% |
| Shares Change (QoQ) | +3.59% |
| Owned by Insiders (%) | 5.57% |
| Owned by Institutions (%) | 23.32% |
| Float | 17.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.56 |
| Forward PS | 20.74 |
| PB Ratio | 1.96 |
| P/TBV Ratio | 1.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.40 |
| Quick Ratio | 12.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -60.54% |
| Return on Assets (ROA) | -32.27% |
| Return on Invested Capital (ROIC) | -36.41% |
| Return on Capital Employed (ROCE) | -47.61% |
| Weighted Average Cost of Capital (WACC) | 7.44% |
| Revenue Per Employee | $1.00M |
| Profits Per Employee | -$2.71M |
| Employee Count | 8 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 3,089 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -42.61% |
| 50-Day Moving Average | 4.61 |
| 200-Day Moving Average | 4.64 |
| Relative Strength Index (RSI) | 27.53 |
| Average Volume (20 Days) | 135,955 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.25M |
| Short Previous Month | 1.19M |
| Short % of Shares Out | 5.35% |
| Short % of Float | 7.15% |
| Short Ratio (days to cover) | 7.79 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 8.02M |
| Gross Profit | -8.97M |
| Operating Income | -20.85M |
| Pretax Income | -21.67M |
| Net Income | -21.67M |
| EBITDA | -20.83M |
| EBIT | -20.85M |
| Loss Per Share | -$1.09 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 43.18M |
| Total Debt | n/a |
| Net Cash | 43.18M |
| Net Cash Per Share | $1.84 |
| Equity (Book Value) | 43.28M |
| Book Value Per Share | 1.84 |
| Working Capital | 43.55M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -15.72M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 19,295 |
| Net Borrowing | n/a |
| Free Cash Flow | -15.72M |
| FCF Per Share | -$0.67 |
Margins
| Measure | Value |
|---|
| Gross Margin | -111.80% |
| Operating Margin | -260.00% |
| Pretax Margin | -270.19% |
| Profit Margin | -270.22% |
| EBITDA Margin | -259.76% |
| EBIT Margin | -260.00% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.38% |
| Shareholder Yield | -22.38% |
| Earnings Yield | -30.17% |
| FCF Yield | -18.57% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.21 |
| Price Target Difference | 321.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 35.00% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 13.8 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |